Literature DB >> 25860234

Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation.

Florian Scherer1, Marcelo A Navarrete2,3, Cristina Bertinetti-Lapatki1, Joachim Boehm4, Annette Schmitt-Graeff5, Hendrik Veelken2.   

Abstract

In B-cells, activation-induced cytidine deaminase (AID) is required for somatic hypermutation (SHM) and class switch recombination (CSR) of immunoglobulin genes. AID introduces mutations in immunoglobulin variable regions (IGV) during B-cell receptor affinity maturation, but may also introduce aberrant mutations into non-immunoglobulin genes, most commonly BCL6. Follicular lymphoma (FL) B-cells constitutively express AID and undergo CSR, SHM and aberrant SHM. We have studied AID expression, the presence of SHM mutations, CSR, and aberrant SHM in BCL6 in a cohort of 75 FL patients. Whereas IgM-expressing (non-switched) FL were characterized by an expected positive correlation between AID and IGV and BCL6 mutations, isotype-switched FL showed dissociation between AID expression and aberrant SHM, and inverse correlation between SHM and AID expression. Our results unveil two manifest biological subgroups of FL and indicate that the specific dissociation between AID and SHM after isotype switch may correlate with the clinical outcome of this heterogeneous disease.

Entities:  

Keywords:  Aberrant somatic hypermutation; B-cell receptor; activation-induced cytidine deaminase; follicular lymphoma; somatic hypermutation

Mesh:

Substances:

Year:  2015        PMID: 25860234     DOI: 10.3109/10428194.2015.1037758

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  CACTUS: integrating clonal architecture with genomic clustering and transcriptome profiling of single tumor cells.

Authors:  Shadi Darvish Shafighi; Szymon M Kiełbasa; Cornelis A M van Bergen; Ewa Szczurek; Julieta Sepúlveda-Yáñez; Ramin Monajemi; Davy Cats; Hailiang Mei; Roberta Menafra; Susan Kloet; Hendrik Veelken
Journal:  Genome Med       Date:  2021-03-24       Impact factor: 11.117

2.  Integration of Mutational Signature Analysis with 3D Chromatin Data Unveils Differential AID-Related Mutagenesis in Indolent Lymphomas.

Authors:  Julieta H Sepulveda-Yanez; Diego Alvarez-Saravia; Jose Fernandez-Goycoolea; Jacqueline Aldridge; Cornelis A M van Bergen; Ward Posthuma; Roberto Uribe-Paredes; Hendrik Veelken; Marcelo A Navarrete
Journal:  Int J Mol Sci       Date:  2021-12-01       Impact factor: 5.923

Review 3.  Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.

Authors:  Eliza M Lauer; Jurik Mutter; Florian Scherer
Journal:  Leukemia       Date:  2022-06-14       Impact factor: 12.883

Review 4.  AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression.

Authors:  Pablo Oppezzo; Marcelo Navarrete; Nicholas Chiorazzi
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

5.  Hydrogen bonds are a primary driving force for de novo protein folding.

Authors:  Schuyler Lee; Chao Wang; Haolin Liu; Jian Xiong; Renee Jiji; Xia Hong; Xiaoxue Yan; Zhangguo Chen; Michal Hammel; Yang Wang; Shaodong Dai; Jing Wang; Chengyu Jiang; Gongyi Zhang
Journal:  Acta Crystallogr D Struct Biol       Date:  2017-11-10       Impact factor: 7.652

6.  High-risk follicular lymphomas harbour more somatic mutations including those in the AID-motif.

Authors:  Taku Tsukamoto; Masakazu Nakano; Ryuichi Sato; Hiroko Adachi; Miki Kiyota; Eri Kawata; Nobuhiko Uoshima; Satoru Yasukawa; Yoshiaki Chinen; Shinsuke Mizutani; Yuji Shimura; Tsutomu Kobayashi; Shigeo Horiike; Akio Yanagisawa; Masafumi Taniwaki; Kei Tashiro; Junya Kuroda
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

7.  Lack of activation-induced cytidine deaminase expression in in situ follicular neoplasia.

Authors:  Tanu Goyal; Sarah L Ondrejka; Juraj Bodo; Lisa Durkin; Eric D Hsi
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.